Table 1 Clinical pharmacology of nondepolarizing neuromuscular blocking agents
From: A fresh look at paralytics in the critically ill: real promise and real concern
NMBA | Peak effect (min) | Recovery (min) | Metabolism | Renal elimination (%) | Biliary elimination (%) | Vagolytic effect | Histamine release | Critical illness polyneuromyopathy |
|---|---|---|---|---|---|---|---|---|
Benzylisoquinolinium | ||||||||
Atracurium | 2-3 | 30-60 | Hoffman Elimination (blood) | 5-10 | None | None | + | + |
Cisatracurium | 1-7 | 40-90 | None | None | None | None | + | |
Aminosteroid | ||||||||
Pancuronium | 2-3 | 80-180 | Liver | 40-70 | 10-15 | +++ | None | +++ |
Rocuronium | 1-2 | 20-60 | 10-30 | 50-75 | + | None | + | |
Vecuroniurn | 2-3 | 40-60 | 15-50 | 35-50 | None | None | +++ | |